Batdelger, D., Dandii, D., Dahgwahdorj, Ya., Erdenetsogt, E., Oyunbileg, J., Tsend, N., Bayarmagnai, B., Jirathitikal, V. and Bourin-baiar, A.S. (2009) Clinical experience with therapeutic vaccines designed for patients with hepatitis. Current Pharmaceutical Design, 15, 1159-1171. doi:10.2174/138161209787846793

has been cited by the following article:

• TITLE: One-month immunotherapy trial in treatment-failed TB patients

  AUTHORS: Olga V. Arjanova, Dmitry A. Butov, Natalia D. Prihoda, Svetlana I. Zaitzeva, Larisa V. Yurchenko, Nina I. Sokolenko, Anna L. Stepanenko, Tatyana S. Butova, Elena A. Grinishina, Olga A. Maksimenko, Vichai Jirathitikal, Aldar S. Bourinbaiar, Valery M. Frolov, Galyna A. Kutsyna

  KEYWORDS: Biomarker; HIV; Inflammation; MDR-TB; Mycobacterium; Survival; Treatment Failure; Vaccine

  JOURNAL NAME: Open Journal of Immunology, Vol.1 No.2, September 30, 2011

  ABSTRACT: reatment failed TB patients have very limited chances of survival. Open label trial of daily oral pill of V-5 Immunitor (V5) was conducted in 48 treatment-failed TB patients on palliative support consisting of isoniazid (H) and rifampicin (R). The subjects had the following forms of TB; cavitary: disseminated: MDR-TB: DR-TB: TB/HIV at 35:13:7:4:1 ratio. After 1 month 62.5% of V5-treated patients experienced negative sputum smear conversion (P 2 respectively (P